Podcasts about Disease

En este episodio exclusivo, LamboRaúl cuenta por primera vez en español su historia completa: cómo pasó de estar hospitalizado con Crohn's Disease y soñar con entrar al ejército, a convertirse en uno de los primeros traders latinos en recibir un payout de más de $100,000 en EE.UU.Raúl revela los inicios duros, su obsesión con educarse en trading, y cómo fue escalando en los mercados de divisas, commodities y futuros. También habla de psicología del trader, errores por ego, cómo construyó su firma de fondeo, y el precio real del éxito.Más allá del dinero y los superdeportivos, este episodio profundiza en la relación con su padre, su transformación espiritual, y lo que realmente le da sentido a su vida hoy: su fe, su familia y ayudar a otros a crecer.Una historia cruda, honesta y poderosa sobre disciplina, caídas, redención y visión. Imperdible.#DalePlay y #LearnWhileInvesting

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

Enjoy these back to back throwback episodes! Doors of Perception is available now on Amazon Prime!https://watch.amazon.com/detail?gti=amzn1.dv.gti.8a60e6c7-678d-4502-b335-adfbb30697b8&ref_=atv_lp_share_mv&r=webMake a Donation to Forbidden Knowledge News https://www.paypal.me/forbiddenknowledgenehttps://buymeacoffee.com/forbiddenThe Forbidden Documentary: Doors of Perception official trailerhttps://youtu.be/F-VJ01kMSII?si=Ee6xwtUONA18HNLZMerchhttps://fknstore.net/Start your microdosing journey with BrainsupremeGet 15% off your order here!!https://brainsupreme.co/discount/FKN15Book a free consultation with Jennifer Halcame Emailjenniferhalcame@gmail.comFacebook pagehttps://www.facebook.com/profile.php?id=61561665957079&mibextid=ZbWKwLWatch The Forbidden Documentary: Occult Louisiana on Tubi: https://link.tubi.tv/pGXW6chxCJbC60 PurplePowerhttps://go.shopc60.com/FORBIDDEN10/or use coupon code knowledge10FKN Link Treehttps://linktr.ee/FKNlinksForbidden Knowledge Network https://forbiddenknowledge.news/ Johnny Larson's artworkhttps://www.patreon.com/JohnnyLarsonSign up on Rokfin!https://rokfin.com/fknplusPodcastshttps://www.spreaker.com/show/forbiddenAvailable on all platforms Support FKN on Spreaker https://spreaker.page.link/KoPgfbEq8kcsR5oj9FKN ON Rumblehttps://rumble.com/c/FKNpGet Cory Hughes Book!Audio bookhttps://buymeacoffee.com/jfkbook/e/392579https://www.buymeacoffee.com/jfkbookhttps://www.amazon.com/Warning-History-Cory-Hughes/dp/B0CL14VQY6/ref=mp_s_a_1_1?crid=72HEFZQA7TAP&keywords=a+warning+from+history+cory+hughes&qid=1698861279&sprefix=a+warning+fro%2Caps%2C121&sr=8-1https://coryhughes.org/YouTube https://youtube.com/@fknclipspBecome Self-Sufficient With A Food Forest!!https://foodforestabundance.com/get-started/?ref=CHRISTOPHERMATHUse coupon code: FORBIDDEN for discountsOur Facebook pageshttps://www.facebook.com/forbiddenknowledgenewsconspiracy/https://www.facebook.com/FKNNetwork/Instagram @forbiddenknowledgenews1@forbiddenknowledgenetworkXhttps://x.com/ForbiddenKnow10?t=uO5AqEtDuHdF9fXYtCUtfw&s=09Email meforbiddenknowledgenews@gmail.comsome music thanks to:https://www.bensound.com/Become a supporter of this podcast: https://www.spreaker.com/podcast/forbidden-knowledge-news--3589233/support.

Support the show

A big old copper beech tree is a focal point of my garden, and each time I look out the window at it admiringly these days, I feel the same love and gratitude I always have for its grandeur –... Read More ›

We’re checking in on how the weather is treating wine grapes. David Korb is the owner, vintner and grape grower at Drumlin Ridge Winery in Waunakee, just North of Madison. Dave is hoping for dry weather these next few months to keep the wine grapes healthy. He's heard of a few issues statewide with winter kill and wind damage.See omnystudio.com/listener for privacy information.

A big old copper beech tree is a focal point of my garden, and each time I look out the window at it admiringly these days, I feel the same love and gratitude I always have for its grandeur –... Read More ›

Hey Heal Squad! We're continuing our theme this week of gut, brain, and emotional healing with this week's throwback with triple board certified physician, Dr. Zach Bush! We knew this was the perfect time to bring back one of our favorite episodes to revisit this week.  Dr. Zach doesn't just talk about symptoms, he gets to the real root of disease: disconnection. Disconnection from our bodies, our relationships, our food, our purpose, and even the Earth itself. He shares how trauma, toxins, gut health, and isolation all play a role in why we're sick, PLUS how healing starts when we finally begin to reconnect on every level. Get ready to shift your perspective on health completely. We talk about the power of nature, the soul-body connection, and why your body isn't broken (it's just been overwhelmed). If you're craving deeper healing and ready to get to the why behind what you're feeling… you don't want to miss this one!  -- HEAL SQUAD SOCIALS IG: https://www.instagram.com/healsquad/ TikTok: https://www.tiktok.com/@healsquadxmaria HEAL SQUAD RESOURCES: Heal Squad Website:https://www.healsquad.com/ Heal Squad x Patreon: https://www.patreon.com/HealSquad/membership Maria Menounos Website: https://www.mariamenounos.com My Curated Macy's Page: Shop My Macy's Storefront Prenuvo: Prenuvo.com/MARIA for $300 off Delete Me: https://bit.ly/43rkHwi   code: SQUAD EMR-Tek Red Light: https://emr-tek.com/discount/Maria30 for 30% off Airbnb: https://www.airbnb.com/  Join the In-Person Heal Retreat: https://www.canyonranch.com/stay/events/heal-retreat-with-maria-menounos/?location=lenox  GUEST RESOURCES: Instagram: https://www.instagram.com/zachbushmd/  Website: https://zachbushmd.com/  ABOUT MARIA MENOUNOS: Emmy Award-winning journalist, TV personality, actress, 2x NYT best-selling author, former pro-wrestler and brain tumor survivor, Maria Menounos' passion is to see others heal and to get better in all areas of life. ABOUT HEAL SQUAD x MARIA MENOUNOS: A daily digital talk-show that brings you the world's leading healers, experts, and celebrities to share groundbreaking secrets and tips to getting better in all areas of life. DISCLAIMER: This Podcast and all related content (published or distributed by or on behalf of Maria Menounos or http://Mariamenounos.com and http://healsquad.com) is for informational purposes only and may include information that is general in nature and that is not specific to you. Any information or opinions provided by guest experts or hosts featured within website or on Company's Podcast are their own; not those of Maria Menounos or the Company. Accordingly, Maria Menounos and the Company cannot be responsible for any results or consequences or actions you may take based on such information or opinions. This podcast is presented for exploratory purposes only. Published content is not intended to be used for preventing, diagnosing, or treating a specific illness. If you have, or suspect you may have, a health-care emergency, please contact a qualified health care professional for treatment.

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

In this episode, Dr Gideon Hirschfield meets with patient advocate Jess Schnur to discuss challenges related to the diagnosis and management of primary biliary cholangitis (PBC) to provide actionable strategies for healthcare professionals to incorporate into patient care, including:Disease concerns and frequently asked questions from a patient perspectiveManaging symptomsTreatment options and supportive careImportance of awareness and educationPresenters:Gideon Hirschfield, MA, MB BChir, FRCP, PhDLily and Terry Horner Chair in Autoimmune Liver Disease ResearchProfessor, Division of Gastroenterology and HepatologyUniversity of TorontoDirector, The Autoimmune and Rare Liver Disease ProgrammeDirector, Francis Family Liver ClinicToronto General Hospital, University Health NetworkOntario, CanadaJess N. Schnur, BSN-RNNational PBC Patient AdvocateAmerican Liver FoundationDonation Support Services CoordinatorLifeline of OhioColumbus, OhioTo learn more, see the programHear Me: Patient Perspectives on PBC

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

This week we discuss nail clippers and Legionnaire's Disease

Today's topic is on corn and pollination, ear sizes, color, health, etc and what we are seeing so far in corn. Corn hybrids are looking well at this time. TOP Ag Services is a Beck's Hybrids seed dealer as well as a franchise partner for Sweetwater Technologies. We provide Hybrid Corn Seed, Soybean Seed, and Wheat Seed. Beck's has access to the best genetics and trait technologies from suppliers worldwide. Through Sweetwater Technologies we have access to industry standard name brand herbicides, insecticides, fungicides, and many others! We have access to biological stress mitigators, biological fertility foliar, and many other products in the category of crop protection and stress prevention. Through our business associates Dirks Bros, we offer fertilizer, soil sampling, and a whole suite of crop nutrition solutions. We are the first to market with the best products & provide the latest, most accurate agronomic information through proven research. If you need agronomic assistance or want to be added to these updates, feel free to reach out via the messaging feature or contact us at topagservices.com/contact or call us at 417-684-5301 to be connected with someone who can help you. All information here is for informational purposes only. It is not a recommendation for your farm. You should not act or refrain from acting on the basis of any content included in this presentation without seeking other professional advice. The contents of this presentation contain general information and may not reflect current agronomic or developments or address your situation. We (Wendell Koehn and all of his affiliates, guests, or assistants) disclaim all liability for actions you take or fail to take based on any content in this presentation.

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

In this episode, we sat down with Max Kane of Farm Match to discuss his healing journey from a debilitating chronic illness. Max shares how he healed his Crohn's Disease without any medication, just whole real (and raw) foods. We discuss how Max created Farm Match which connects food producers to consumers, the power of real foods, the stigma around raw meat and dairy, and more.Show references:1920's playgroundFind Farm MatchInstagram // @farmmatchWebsite // https://www.farmmatch.com/Youtube // https://www.youtube.com/@maxkane4302Find HomegrownInstagram // @Homegrown_education, @lizhaselmayer, @joeyhaselmayerWebsite // https://www.homegrowneducation.org/Natural home goods // Haselmayer GoodsFrom long-term disability to vibrant health—how Max Kane of Farm Match conquered chronic illness with real (raw) food

In this special episode of Health Matters, we explore the power of storytelling in a health journey. As part of the Art of Wellbeing series at Lincoln Center, a collaborative effort with NewYork-Presbyterian, the official Hospital for Lincoln Center for the Performing Arts, we attend a storytelling workshop with The Moth, a nonprofit dedicated to the art and craft of storytelling. The workshop guided attendees through telling a personal story about their own health, led by an expert instructor. Health Matters host Courtney Allison discusses the healing power of storytelling with workshop facilitator, Anna Roberts, and reflects on the importance of stories with Dr. Rita Charon, a general internist, founder of the field of narrative medicine, and chief of the Division of Narrative Medicine at Columbia. Dr. Charon helps train doctors to be better listeners so that they can treat the whole patient.Click here to learn more about the Art of Wellbeing and upcoming events.___Dr. Rita Charon is a general internist and literary scholar who originated the field of narrative medicine. She is Professor and Founding Chair of the Department of Medical Humanities and Ethics and Professor of Medicine at Columbia University. She completed her MD at Harvard in 1978 and PhD in English at Columbia in 1999, concentrating on narratology. Her research focuses on the consequences of narrative medicine practice, narrative medicine pedagogy, and health care team effectiveness.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Idaho Matters sits down with one doctor who is committed to patient care and educating the physicians of tomorrow.

Steve and Virginia sit down with Andrea Hughes, a dedicated caregiver whose mother was diagnosed with early-onset Alzheimer's Disease. Featured in the PBS documentary Matter of Mind: My Alzheimer's, Andrea shares her personal journey navigating the challenges of caregiving at a young age, balancing work and family responsibilities, and finding strength through community and storytelling. To learn more, visit the PBS documentary page, follow Andrea on Instagram @itsandreakrystal, and explore her work at candidcaregiverscollective.com.

In this episode, Daniel C. Butler, MD, and Shawn G. Kwatra, MD, discuss the practical considerations for using IL-13 inhibitors to treat patients with moderate to severe atopic dermatitis, including:Patient candidacy considerationsTreatment advancement strategies that go beyond topical therapiesThe importance of patient-centered care that address patients' fears and needsA detailed patient case to highlight take home pointsPresenterDaniel C. Butler, MD​Assistant Dean Student Affairs​University of Arizona College of Medicine – Tucson​Tucson, ArizonaShawn G. Kwatra, MD​Dr. Joseph W. Burnett Endowed Professor and Chair ​Department of Dermatology​University of Maryland School of Medicine​Baltimore, MarylandProgram page:https://bit.ly/4kTP04D

In this episode, Andrew F. Alexis, MD, MPH; Daniel C. Butler, MD; and Shawn G. Kwatra, MD, discuss IL-13 inhibition for treating patients with moderate to severe atopic dermatitis (AD), including:The available biologic therapies that specifically target IL-13Where these agents fall in the 2024 American Academy of Dermatology treatment algorithmHow these agents compare to other AD therapies like topical corticosteroids and oral JAK inhibitorsA detailed patient case to highlight take home pointsPresenterAndrew F. Alexis, MD, MPH​Professor of Clinical Dermatology​Weill Cornell Medical College ​New York, New YorkDaniel C. Butler, MD​Assistant Dean Student Affairs​University of Arizona College of Medicine – Tucson​Tucson, ArizonaShawn G. Kwatra, MD​Dr. Joseph W. Burnett Endowed Professor and Chair ​Department of Dermatology​University of Maryland School of Medicine​Baltimore, MarylandProgram page:https://bit.ly/4kTP04D

We're celebrating God's faithfulness in letting us release 100 episodes of Compelled! Show notes (including all the mentioned episodes) @ https://compelledpodcast.com/episodes/celebrating-100-episodes Zach Fowler's favorite episodes:  #05 A Spiritual Suicide - Phillip Telfer: https://compelledpodcast.com/episodes/phillip-telfer #17 Doubts. Depression. Disease. - Ryan Dobson: https://compelledpodcast.com/episodes/ryan-dobson Becky Hetrick's favorite episode: #27 9/11 Survivor at the Pentagon - Brian Birdwell: https://compelledpodcast.com/episodes/brian-birdwell Atley Nugent's favorite episodes: #90 Healing After Rape - Teri Hrabovsky: https://compelledpodcast.com/episodes/teri-hrabovsky #86 Skipping Retirement. Living on Mission. - Brian Lynn: https://compelledpodcast.com/episodes/brian-lynn Will Jackson's favorite episodes: #65 Among the Cannibals & Headhunters - Steve Richardson: https://compelledpodcast.com/episodes/steve-richardson #87 KKK Terrorist Finds Christ - Tom Tarrants: https://compelledpodcast.com/episodes/tom-tarrants Tim Hull's favorite episodes: Tom Tarrants (see link above) #30 Forgiving My Kidnappers - Gracia Burnham: https://compelledpodcast.com/episodes/gracia-burnham Micah Foster's favorite episodes: #60 A Broken Man's Miraculous Fight for the Unborn - John Barros: https://compelledpodcast.com/episodes/john-barros #16 Falsely Accused & Sentenced to Life in Prison - Hannah Overton: https://compelledpodcast.com/episodes/hannah-overton Mark Weeber's favorite episode: #28 The Blessing of Disability - Jonathan Pacheco, Part 1: https://compelledpodcast.com/episodes/jonathan-pacheco-pt-1 Episodes that Paul mentioned #​42 Grief in Afghanistan: Testimony from a U.S. Navy Special Ops Teammate - Jim Payne: https://compelledpodcast.com/episodes/jim-payne #92 The Witness - Steven Matamoros: https://compelledpodcast.com/episodes/steven-matamoros Want to help us make the next 100 episodes of Compelled? Either make a one-time gift, or become a Monthly Partner at: https://compelledpodcast.com/donate ++++++++++++ Compelled is a seasonal podcast using gripping, immersive storytelling to celebrate the powerful ways God is transforming Christians around the world. These Christian testimonies are raw, true, and powerful. Be encouraged and let your faith be strengthened! Want to help make new episodes? Either make a one-time gift, or become a Monthly Partner at: https://compelledpodcast.com/donate Perks of being a Monthly Partner include: EARLY ACCESS to each new Compelled episode 1 week early! FULL LIBRARY of our unedited, behind-the-scenes interviews with each guest... over 100+ hours of additional stories and takeaways! Become a Monthly Partner by selecting the "Monthly" option during check-out.  Show notes, emails, and more at: https://compelledpodcast.com Compelled is a member of the Proclaim Podcast Network: https://proclaim.fm Learn more about your ad choices. Visit megaphone.fm/adchoices

TED Fellow and equity bioengineer Erika Moore investigates how cells controlling inflammation behave differently depending on a patient's background. By focusing on the "who" behind the disease, Moore is uncovering why certain diseases disproportionately affect certain ethnicities, paving the way for more inclusive and effective health care.Want to help shape TED's shows going forward? Fill out our survey!Become a TED Member today at https://ted.com/join Hosted on Acast. See acast.com/privacy for more information.

It's clear that artificial intelligence is going to be one of the most powerful forces shaping the future of humanity and the planet today and over the next two decades. Much of the AI discourse is negative or dystopian themed. Far too little AI news is highlighting how the planet's problems and the challenges humans face can be solved. In this conversation, futurist Jack Uldrich paints a picture of how we can collectively benefit from the advancements in artificial intelligence. Given the moving target of forecasting the future, Jack provides AI scenarios that he is 99% certain will occur, 75% certain, and 50% certain. He even provides a few scenarios that have a 25% and even 1% chances of happening. Jack says that we will see great leaps in diagnosing cancer and Alzheimer's Disease sooner. He is optimistic that AI can be used to address the effects of climate change and greatly assist in the pursuit of nuclear fusion. In what is becoming known as the “compressed century” - where there will be a century's worth of change in just a decade, Jack points out that “AI is doubling in capacity and capability every seven months” which means that the capabilities of AI in six years could be a thousand times more powerful than they are today. Jack doesn't see AI as a panacea. He points out that there will be job losses because of AI. He says that trust could be further eroded as a result of AI-generated deep fakes and fake news. He also points out that the “internet is broken” as we move from “social media to social production.” The conversation ends with Jack sharing his ideas around how purpose, faith, and trust will grow in importance to cope with the disruption AI is certain to bring. Jack Uldrich is a well-recognized global futurist, speaker, and the author of thirteen books, including a number of award-winning best sellers. He is a frequent speaker on technology, change management and leadership and has addressed hundreds of corporations, associations and not-for-profit organizations on five continents. He regularly makes television appearances on PBS's Frontline, the Science Channel, and the Discovery Channel, and is a frequent guest on major media outlets, including CNN, CNBC, Fox and National Public Radio.

Episode 39 - Actor and personal trainer Ollie McFarlane talks career, funny stories and overcoming 5 surgeries for short segment Hirschsprung's Disease to follow his dream of acting. Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

Learn how to choose the best companion plants for your fruit trees, build simple and effective guilds, and avoid common mistakes.Permaculture educator, co-founder of the Shenandoah Permaculture Institute, and co-author of Mulberries in the Rain: Growing Permaculture Plants for Food and Friendship, Ryan Blosser shares plant combinations that work — and the stories behind them — from dynamic accumulators to barrier plants, beneficial insect attractors, and more.The host of the Orchard People radio show and podcast is Susan Poizner of the fruit tree care education website www.orchardpeople.com.  Susan is the author of four books on fruit tree care. Learn more here: https://learn.orchardpeople.com/booksShe is also the creator of five-star rated premium online fruit tree care education at: https://learn.orchardpeople.comHOW TO TUNE IN TO OUR PODCASTThe show airs on the last Tuesday of every month on RealityRadio101 at 1:00 PM ET! While it's no longer live, you can still watch or listen anytime—and catch the recorded podcast anytime afterward.

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

Work has officially begun to create a new National Biosecurity Centre. It's being built on the existing Animal and Plant Health Agency (APHA) site, at Weybridge in Surrey. The whole project is costing between two and three billion pounds and is expected to take until 2033 to complete. The APHA was recently criticised by the National Audit Office, which said facilities there were not adequate to prevent or cope with contiguous national animal disease outbreaks such as foot and mouth and avian flu. However, the government says it is putting that right by the upgrade, which will ensure that the threat of animal diseases, which could be passed to humans, are prevented or dealt with efficiently. Unreliable mobile phone signal is a common complaint on many farms. Connectivity isn't just about messaging or making calls. Using apps and uploading data are an increasingly important part of everyday farming. Could part of the solution be private, portable digital  5G networks? We visit a farm thathas been trialling such a system.All week we're meeting the next generation of agricultural talent; whether it be farmers, foresters, land managers or agronomists. Thousands of young people will graduate from agricultural courses, across the UK this summer and all week, we'll be finding out what they hope to achieve, and what jobs they are looking forward to. We meet students from Moulton College in Northamptonshire who have just completed their agricultural studies.Presenter: Anna Hill Producer: Rebecca Rooney

Investigative journalist Charles Piller explains the remarkable story of fraud he has uncovered in Alzheimer's Disease research, which he discusses in a new book: Doctored: Fraud, Arrogance and Tragedy in the Quest to Cure Alzheimer's. Charles argues the result of this is that Alzheimer's research and treatment has been set by years - if not decades. He goes on to discusse the trial data on which several Alzheimer's drugs, including Aducanumab, Lecanemab and Donanemab, were approved. Charles says the data is unconvincing and  the side effects – including brain swelling and bleeding -  concerning. Doctored: Fraud, Arrogance and Tragedy in the Quest to Cure Alzheimer's by Charles Piller is published by Icon Books. Charles Piller is an investigative journalist who works for the journal Science. His work has also been published in a number of other publications including The New York Times and the Los Angeles Times. Charles has won a number of journalism awards for his work and is also the author of the books Gene Wars and The Fail-Safe Society. The host of the podcast, Liz Tucker is an award winning medical journalist and former BBC producer and director.  You can follow Liz on Twitter at https://twitter.com/lizctucker and read her Substack newsletter about the podcast at https://liztucker.substack.com If you would like to support this podcast you can do so via Patreon at https://www.patreon.com/WhatYourGPDoesntTellYou or via PayPal at https://www.whatyourgpdoesnttellyou.com/support/ What Your GP Doesn't Tell You has been selected by Feedspot as one of the top 15 UK Medical Podcasts https://blog.feedspot.com/uk_medical_podcasts/

In this episode, Andrew F. Alexis, MD, MPH, and Daniel C. Butler, MD, discuss the immunopathogenesis and role of IL-13 in atopic dermatitis (AD), including:Contributors to epidermal barrier dysfunction (eg, environmental triggers)IL-13 as a key cytokine in AD pathogenesisTargeted AD therapies that inhibit IL-13A detailed patient case to highlight take-home pointsPresenterAndrew F. Alexis, MD, MPH​Professor of Clinical Dermatology​Weill Cornell Medical College ​New York, New YorkDaniel C. Butler, MD​Assistant Dean Student Affairs​University of Arizona College of Medicine – Tucson​Tucson, ArizonaProgram page: https://bit.ly/4kTP04D

Beech leaf disease was found in 43 towns last year, and scientists are searching beyond those borders to see if the disease is spreading farther.

In this episode of the RCP Medicine podcast, Professor Ailsa Hart and Dr Eathar Shakweh discuss how to approach managing Inflammatory Bowel Disease (IBD) in the acute medical setting. This is the second episode of a 2-part series, with a focus on Crohn's disease. IBD is a common condition, affecting 1 in 123 people in the UK. The 2024 State of the IBD Care in the UK report highlighted the urgent need to shorten time to diagnosis and initiate early treatment to minimise the risk of IBD-related complications. Acute and general medicine physicians have an important role to play in diagnosing and managing IBD. This podcast will equip medics at all stages of training with the necessary knowledge to approach this heterogenous and complex condition. Professor Hart is Director of IBD Research at St Mark's Hospital, London, United Kingdom and a world-leading expert in IBD. Eathar is an IBD Clinical Research Fellow at St Mark's and Imperial, with a special interest in perianal fistulising Crohn's disease. Crohn's & Colitis UK (CCUK) Websitehttps://crohnsandcolitis.org.uk/This is a valuable resource for patients and healthcare professionals alike, containing a wealth of information on IBD investigation and management.British Society of Gastroenterology (BSG) guidelines on Inflammatory Bowel Disease (IBD) - 2019Lamb, Christopher Andrew et al. “British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.” Gut vol. 68,Suppl 3 (2019): s1-s106. doi:10.1136/gutjnl-2019-318484https://pubmed.ncbi.nlm.nih.gov/31562236/For interested listeners, these are the national guidelines for IBD diagnosis and management. Please note, the new guidelines for 2025 are pending release.ECCO Guidelines on Therapeutics in Crohn's disease: Medical TreatmentTorres, Joana et al. “ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.” Journal of Crohn's & colitis vol. 14,1 (2020): 4-22. doi:10.1093/ecco-jcc/jjz180https://pubmed.ncbi.nlm.nih.gov/38877997/ECCO Guidelines on Surgery in Crohn's disease: Surgical TreatmentAdamina, Michel et al. “ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.” Journal of Crohn's & colitis vol. 18,10 (2024): 1556-1582. doi:10.1093/ecco-jcc/jjae089https://pubmed.ncbi.nlm.nih.gov/38878002/These are the European Crohn's and Colitis Organisation (ECCO) guidelines on therapeutics in Crohn's disease, divided into medical and surgical treatment.RCPEducation and learning | RCP CreditsMusic bensound.com

On this New Movie Monday we return back to an England overrun by the Rage Virus Plague. We discuss the newest addition to the franchise and mythology since 28 Days Later, the new evolution and super powers of the Rage Virus Zombies, and the many versions of family in the Apocalypse. This is a huge movie that shoves in a lot of ideas and even some insane camp. Make sure you see this one on the biggest screen possible! Synopsis: A group of survivors of the rage virus live on a small island. When one of the group leaves the island on a mission into the mainland, he discovers secrets, wonders, and horrors that have mutated not only the infected but other survivors.  Starring: Jodie Comer, Aaron Taylor-Johnson, Ralph Fiennes, Alfie Williams, Jack O'Connell Written by Alex Garland Directed by Danny Boyle  Help us make our first feature length Messed Up Movie: https://www.misfitparade.com/mrcreamjeans Support the show on the Patreon: https://www.patreon.com/c/messedupmoviespod Watch our newest short film Sugar Tits Now! https://www.youtube.com/watch?v=Sz7leFqqo4g  

06 23 25 Corn Leaf Diseases and Fungicides by Ag PhD

Following the publication of Baroness Louise Casey's highly critical report into grooming gangs involved in the sexual exploitation of children, we look at one of her 12 recommendations in detail. The Home Secretary, Yvette Cooper, has committed to reviewing the criminal convictions of victims of child sexual exploitation, quashing the criminal records of victims who were “criminalised instead of protected”. Nuala McGovern speaks to Jade, who as a teenager was charged with a grooming offence and is trying to get that conviction overturned. Nuala also hears from Paula Harriott, the CEO of the charity Unlock. Students will spend an average of 25 years on their phones over their lifetime. The average person in school, college or university spends five hours and 30 minutes a day on their mobile, according to a new study by the app, Fluid Focus. Last year Ofcom found that across all adult age groups, women are spending more time online – that's on smartphones, tablets and computers – than men - clocking up an extra 33 minutes more each day. Nuala speaks to Sunday Times journalist Charlotte Ivers about her phone use. More than half of Heart Valve Disease (HVD) cases are women, yet less than half of heart valve surgeries and procedures are on women, according to new data from the charity Heart Valve Voice. Heart valve disease is when one or more of your heart valves do not work like they should. This can affect blood flow and put extra strain on the heart. How can women's symptoms be taken more seriously? Nuala is joined by cardiologist Dr Alison Duncan and HVD patient Jaqueline, who was initially misdiagnosed with anxiety.Three years on since the war with Russia began, more and more young women are choosing to leave the country to continue their lives in Europe, either studying or working. Young men have been banned from leaving Ukraine after they turn 18 since the war broke out and martial law was introduced, but young women are free to leave. Freelance journalist Gabriella Jozwiak has been in the city of Lviv talking to young women about their plans for the future, and joins Nuala. Presenter: Nuala McGovern Producer: Emma Pearce

There are several breeding methods available to breeders for creating a strain. Each method serves a specific function and purpose. Understanding when and how to apply these methods significantly contributes to a breeder's success in establishing a true strain. However, many breeders are hesitant to practice inbreeding due to concerns about inbreeding depression. Instead, they often resort to outcrossing, believing it to be a universal solution. In this episode, we explore these breeding methods in depth, examining their respective forms and functions. Today, we challenge you to reconsider traditional breeding practices and their enduring impacts. Continual reliance on outcrossing risks disrupting the gene pool, thereby threatening the preservation of breeds and bloodlines. Join us for a discussion on this contentious yet crucial topic. Welcome to Bred to Perfection with Kenny, Nancy, and Frank – the go-to podcast for serious breeders who want to master the art and science of selective breeding. Hosted by master breeder Kenny Troiano, his wife and co-host Nancy Troiano, and fellow breeder Frank Bradley, this show talks about the principles of genetics, strain development, health management, and everything you need to breed, raise and maintain high-quality chickens and gamefowl. Each episode offers practical advice, expert interviews, live Q&A sessions, and real-world insight drawn from decades of hands-on experience. Backed by the Breeders Academy, our online learning platform, Bred to Perfection equips breeders of all levels with the knowledge and tools to build strong, sustainable, and productive breeding programs. New to the show? We're glad you're here! Tune into today's episode to get a feel for what Bred to Perfection is all about. Whether you're just starting out or refining your own strain, you'll find something valuable in every conversation. Fridays at 6 PM PST / 9 PM EST on YouTubeJoin Kenny Troiano and guests as they explore advanced breeding techniques, poultry nutrition, health management, and genetic sustainability—all with one goal: helping you create high-quality, long-lasting strains. See ya there! Kenny Troiano Founder of "The Breeders Academy"  We specialize in breeding, and breeding related topics. This includes proper selection practices and the use of proven breeding programs. It is our mission to provide our followers and members a greater understanding of poultry breeding, poultry genetics, poultry health care and disease prevention, and how to improve the production and performance ability of your fowl.  If you are interested in creating a strain, or improving your established strain, you are in the right place.  We also want to encourage you to join us at the Breeders Academy, where we will not only help you increase your knowledge of breeding and advance your skills as a breeder, but improve the quality and performance of your fowl. If you would like to learn more, go to: https://www.breedersacademy.com

In 2025, Creating Dementia Solutions is looking deeper into what The Lancet Commission on dementia prevention, intervention and care has indicated are ways people can reduce their risk of dementia.Lancet includes Diabetes treatment as one of those ways. In this episode, T R Shaw tells us how the Cereal City Sunrise Rotary Club has developed an action group in hopes of growing awareness about the disease and how its treated.Episode ResourcesThe Lancet Commission Risk Factors for DementiaMiles for Memories websiteMiles for Memories technologySherii Sherban talks to Community Matters about MFM technologyMore Creating Dementia Solutions episodes ABOUT MILES FOR MEMORIESMiles For Memories is a Calhoun County, Michigan organization created in 2013 to raise awareness and funds for Alzheimer's Disease. Later in 2014, the vision was expanded to include all types of dementia. MFM raises money each year through sponsorships, community events, and grants to gather funds to create local programming for both the person living with dementia and the caregiver. Along with local efforts, 20% of the funds to prevention-related dementia research. Miles for Memories is a committee of 70-plus volunteers and are always looking for more to get involved.

The essence of Being Human is the practice of Biocultural Reproduction (BCR). BCR is defined as the set of marriage and kinship based rules for extra-maternal cooperation in the production, feeding, and care of offspring. Human evolution theory needs to explain how people successfully combined a vastly extended period of offspring dependency and delayed reproduction with helpless newborns — with large heads and much body fat (even with problems giving birth) -- a short duration of breast-feeding, an adolescent growth spurt, and vigorous post-menopause valuable grandmothers. Are these characteristics a package or a mosaic? Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40697]

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CMF865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Moving the Efficacy NeedleWith Immunotherapy in Melanoma: Modern Standards and Next-Gen Strategies in Resectable and Unresectable Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and AIM at Melanoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Iovance Biotherapeutics.Disclosure information is available at the beginning of the video presentation.

06/22/25The Healthy Matters PodcastS04_E18 - The ABCs of COPDWith Special Guest:  Dr. Caroline Davis, MDDid you know that 6.5% of Americans have physician-diagnosed Chronic Obstructive Pulmonary Disease (COPD)?  That's a pretty staggering statistic...  You might think that people get it from smoking, and well, you'd be right.  But that's not the only thing that can cause it!  COPD is a disease of the airways where people have difficulty getting air out  of there lungs.  But why is that an issue?  Who's most likely to be afflicted with this condition?  And best yet, how can you avoid it altogether?Joining us on Episode 18 of our show is Dr. Caroline Davis, a pulmonologist at Hennepin Healthcare, and just the expert to help us get to the bottom of some of these questions.  We'll go over the common causes of COPD, who's at risk, the current and future treatments available, and how this condition differs from other afflictions, like emphysema and asthma.  COPD can be a serious disease, but there are a lot great treatments available, and believe us when we say that at the end of this episode, you'll be breathing a little easier.  Join us!We're open to your comments or ideas for future shows!Email - healthymatters@hcmed.orgCall - 612-873-TALK (8255)Get a preview of upcoming shows on social media and find out more about our show at www.healthymatters.org.

Welcome to my first solo AMA episode in quite some time!  I recently submitted the second round of edits for my book. That excited me and inspired me to reach out on social media and invite questions from my listeners and community. In my conversation today, I dive into weight loss resistance and reverse dieting, and I also share what I have been doing over the past year to build muscle.  Join me for a transparent and candid conversation, interwoven with questions from listeners and social media followers, where I answer many of the questions that matter most to you. IN THIS EPISODE, YOU WILL LEARN: Why the death of my father inspired me to back away from fasting and focus on strength training Changing my mindset to prioritize strength over thinness How the sex hormone shifts during perimenopause and menopause affect body composition The benefits of reverse dieting to improve metabolic health          Using strength training to counteract the effects of sarcopenia Chronic stress and its impact on cortisol levels and metabolic health inflammation levels and toxins from personal care products, food, and the environment Importance of prioritizing sleep  Connecting with hormone-savvy healthcare providers The best supplements for overall health Connect with Cynthia Thurlow   Follow on Twitter Instagram LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Books mentioned: Estrogen Matters: Why Taking Hormones in Menopause Can Improve Women's Well-Being and Lengthen Their Lives—Without Raising the Risk of Breast Cancer by Dr. Avrum Bluming and Dr. Carol Tavris The XX Brain: The Groundbreaking Science Empowering Women to Maximize Cognitive Health and Prevent Alzheimer's Disease by Lisa Mosconi

Ultraprocessed foods are everywhere — and a lot of them are making us sick! These industrially processed foods are being linked to 32 different diseases, including type 2 diabetes, obesity, heart disease, cancer, and depression.    But UFPs make up more than HALF the foods we eat. More when it comes to the diets of children and young people. And it's no wonder — even foods marketed as "healthy" choices fall into this category.    So how do you know what's safe, and what's making you sick? Are all of them unhealthy?   Dr. Neal Barnard is here to guide us. He joins Chuck to explain how this one category of food is quietly fueling a public health crisis — and how you can protect yourself.   You'll learn: What qualifies as an ultraprocessed food — and why it matters– The difference between a healthy and unhealthy processed food– How these foods are designed to be addictive and override your hunger cues– What the latest research says about chronic disease risk– Simple, affordable swaps to cut ultraprocessed foods from your diet   Whether you're trying to lose weight, prevent disease, or eat more mindfully, this episode gives you the tools to take control of your health — starting with what's on your plate.   This episode is sponsored by The Gregory J. Reiter Memorial Fund, which supports organizations like the Physicians Committee that carry on Greg's passion and love for animals through rescue efforts, veganism, and wildlife conservation.   — — SHOW LINKS — — JAMA Processed Food Study https://bit.ly/UPFsHealthStudy — — — Gregory J. Reiter Memorial Fund https://gregoryreiterfund.org — — EVENTS — — NHA Conference Where: Cleveland, OH When: June 26-29, 2025 Tix & Speakers: https://bit.ly/NHAtix2025 20% off virtual tickets with code: PCRM20 $100 off in-person tickets with code: PCRM100 — — — International Conference on Nutrition in Medicine Where: Washington, DC When: August 14-16, 2025 Tix & Speakers: https://www.pcrm.org/icnm $50 off tickets with code: NUTRITION50 — — BECOME AN EXAM ROOM VIP — — Sign up: https://www.pcrm.org/examroomvip — — THIS IS US — — The Exam Room Podcast Instagram: https://www.instagram.com/theexamroompodcast — — — Chuck Carroll Instagram: https://www.instagram.com/ChuckCarrollWLC Facebook: https://www.facebook.com/ChuckCarrollWLC X: https://www.twitter.com/ChuckCarrollWLC — — — Physicians Committee Instagram: https://www.instagram.com/physicianscommittee Facebook: https://www.facebook.com/PCRM.org X: https://www.twitter.com/pcrm YouTube: https://www.youtube.com/user/PCRM Jobs: https://www.pcrm.org/careers — — SUBSCRIBE & SHARE — — 5-Star Success: Share Your Story Apple: https://apple.co/2JXBkpy​​ Spotify: https://spoti.fi/2pMLoY3 Please subscribe and give the show a 5-star rating on Apple Podcasts, Spotify, or many other podcast providers. Don't forget to share it with a friend for inspiration!

As a pre-teen, Eryn Lynum was diagnosed with Addison's Disease. As an adult, she became a naturalist. Both taught her that rest isn't a luxury—it's a vital, God-given activity designed to fuel everything else you do. Scriptures referenced:2 Timothy 2:15Romans 1:20Matthew 11:28-30Isaiah 40:28John 10:10Exodus 16Dive deeper: The Nature of Rest: What the Bible and Creation Teach Us About Sabbath LivingMore from Eryn: Website | Podcast | Family Values GuideEryn's favorites: NASB 1995 | ESV Thompson Chain-Reference Bible | Fine-Tip Sharpie Pens | Gel Pens | Blue Letter Bible | Logos Bible SoftwareClick here to send us your email for our newsletter OR to send a message to the show! We have no way of responding unless you leave your email.Join our community! If you are a Christian woman seeking to know God deeper, study Scriptures, pray with and for others, strengthen your faith, and support other in doing the same, this is the place for you. Want to study God's Word for yourself? Try our In-Depth Bible Study Academy Click here to try a free mini-course!

Questions about how we can be guilty when we sin if sin is a disease we're born with, how it can be that we'll have free will in Heaven but not have the ability to choose to sin, and whether morality and logic are correct because God says so or he says so because they're correct.   If sin is a disease we're all born with, how can we be guilty when we sin? Can you explain how we will retain free will in Heaven but will not have the ability to choose to sin? Is morality correct because God says so, or does he say so because it is correct? Is logic correct because God says so, or does he say so because it is correct?

This week Nate's immune system learns about Hand, foot, and mouth disease, bilungual babies, and white supremecist Mickey Mouse. New Shirt! Come Scream with me https://www.hellofawaytodie.com/products/come-scream-with-me-unisex-shirt If you like this and are craving more, Subscribe to our Patreon and get access to more than eight years of bonus content. Three new episodes a month- https://www.patreon.com/Hellofawaytodie  Check out the store, new updates every week - https://whatahellofawaytodad.com/  

If you've felt like chronic illnesses are on the rise, unfortunately, you're right. I'm joined by Michelle Shapiro, an integrative and functional registered dietitian, to dive into why this is happening, what we can do to prevent chronic illnesses and autoimmune diseases, how we can manage systems if we are ill with practical steps and tools, and what treatment options we should explore. We also discuss the science of exactly what's happening in our bodies and how our immune system, nervous system, diet, and environment are all connected. In this episode, we get into: The Rise of Chronic Diseases & Autoimmune Diseases Managing Chronic Conditions Treatment Options Practical Advice for Managing Symptoms Handling the “It's All In Your Head” Skepticism Long COVID, Mast Cell Activation Syndrome (MCAS), POTS, Hashimoto's Disease, Crohn's Disease, Parasites, Mold, SIBO, Candida, Leaky Gut, Hypermobility, & Histamine Issues For more from Michelle Shapiro, find her on Instagram @michelleshapirord or online at https://michelleshapirord.com/. Check out her podcast, Quiet the Diet and her Highly Sensitive Body Hub discussed in the episode. Brain retraining programs for chronic conditions mentioned in this episode from Michelle include the Gupta Program and the Primal Trust Program. Ready to uplevel every part of your life? Order Liz's book 100 Ways to Change Your Life: The Science of Leveling Up Health, Happiness, Relationships & Success now!  Connect with Liz on Instagram @lizmoody or online at www.lizmoody.com. Subscribe to the substack by visiting https://lizmoody.substack.com/welcome. To join The Liz Moody Podcast Club Facebook group, go to www.facebook.com/groups/thelizmoodypodcast. This episode is brought to you completely free thanks to the following podcast sponsor: LMNT: go to DrinkLMNT.com/LIZMOODY to get a free LMNT sample pack with any order. The Liz Moody Podcast cover art by Zack. The Liz Moody Podcast music by Alex Ruimy. Formerly the Healthier Together Podcast.  This podcast and website represents the opinions of Liz Moody and her guests to the show. The content here should not be taken as medical advice. The content here is for information purposes only, and because each person is so unique, please consult your healthcare professional for any medical questions. The Liz Moody Podcast Episode 339. Learn more about your ad choices. Visit megaphone.fm/adchoices

Scott Porter (Ginny & Georgia, Friday Night Lights) joins me this week to discuss his transition from singing wide receiver to acting and how his pursuit in Hollywood allowed him to reconnect with lost family. Scott talks about the unexpected challenges and growth he's experienced on Ginny & Georgia, including the surprises of the ‘balance' show's success on Netflix. We also get into overcoming anxiety before performances, his passion for spreading awareness for Huntington's Disease, and learning the most when a situation goes wrong. Thank you to our sponsors:

Episode Highlights With DaniHer 24 years spent with chronic lifestyle diseases like IBS, Lupus, urticaria, and othersShe was 24 years in before a doctor asked what she was eating If you were born healthy… you do not have to live sick!How quickly the body can adapt when given the right inputsHealing is incredibly simple, but not easyShe starts with diet first and then builds from there… the importance of single-ingredient foodsReal food goes bad… auditing your food choices, and cooking is self-careThe top seven most inflammatory foods in the modern diet and why she does food sensitivity testImportance of sleep and how if we don't sleep, we don't healBallroom dancing is the number one way to decrease Alzheimer's and dementia riskHow data shows that community is extremely important to healthWe are a nation of empty vessels Rest and self-care are so important, and we often forget these- you cannot serve from an empty vesselResources MentionedDani Williamson - WebsiteWild & Well: Dani's Six Commonsense Steps to Radical Healing by Dani Williamson